LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Novel Gene Methylation Panel Paves Way for Esophageal Cancer Blood Test

By LabMedica International staff writers
Posted on 30 Dec 2024
Print article
Image: A new DNA methylation biomarkers panel holds promise as a non-invasive, convenient diagnostic test for esophageal cancer (Photo courtesy of 123RF)
Image: A new DNA methylation biomarkers panel holds promise as a non-invasive, convenient diagnostic test for esophageal cancer (Photo courtesy of 123RF)

Esophageal cancer (EC) is the 7th most commonly diagnosed cancer and ranks as the 6th leading cause of cancer-related deaths worldwide. Currently, the diagnosis of EC relies on methods such as imaging, sponge cytology testing, and endoscopy. While endoscopy is recommended for individuals at high risk of EC, it is not suitable for large-scale screening of the general population due to its invasive, inconvenient, and time-consuming nature. To overcome these challenges, it is essential to improve diagnostic techniques and develop effective screening strategies for at-risk populations. In recent years, several blood-based biomarkers—such as tumor-associated proteins, cell-free DNA (cfDNA), cell-free RNA (cfRNA), miRNA, and other tumor-derived metabolites—have been extensively researched for their potential in clinical applications. Among these, cfDNA, which consists of extracellular DNA fragments released by cells undergoing regulated metabolism or pathological secretion, has shown significant promise in enhancing cancer detection and management. Now, a new study has led to the creation of a gene methylation panel for a blood test aimed at diagnosing EC.

Researchers at Henan Cancer Hospital (Zhengzhou, China) conducted the study using a cohort of 304 participants, including 203 patients with EC and 101 controls. The research focused on DNA methylation levels of SEPTIN9, tissue factor pathway inhibitor 2 (TFPI2), and the fragile histidine triad gene (FHIT) in patients with EC, benign esophageal diseases, and healthy controls. The findings showed significantly higher DNA methylation levels of SEPTIN9, TFPI2, and FHIT in patients with EC compared to those with benign esophageal conditions or healthy individuals. The panel demonstrated considerable potential as a non-invasive tool for distinguishing malignant tumors from both healthy controls and benign esophageal diseases. Specifically, it showed excellent diagnostic efficiency for stage 0, I, and II cancer patients, with sensitivities of 69.0%, 75.5%, and 78.9%, respectively.

The comparison of results between RT-PCR testing and the gold standard of pathological examination revealed a Kappa value of 0.725, indicating a high level of consistency. Furthermore, there was no significant variation in diagnostic efficiency based on age, gender, or the presence of other malignancies. The study’s findings, published in the journal BMC Cancer, suggest that the DNA methylation biomarkers panel offers a promising, non-invasive diagnostic method for EC. The panel’s ability to differentiate between malignant tumors and benign esophageal diseases, along with its high sensitivity and specificity, offers valuable potential for improving the diagnosis of high-risk populations when used in combination with existing detection methods.

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit
New
High Performance Centrifuge
CO336/336R

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.